Every Form 4 that Climb Bio, Inc. (CLYM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLYM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLYM filings page.
Climb Bio, Inc. (CLYM) director Thomas Stephen Basil reported selling 100,000 shares of common stock on September 15, 2026 at a weighted average price of $13.6682 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on June 16, 2026. After these sales, he reported owning 467,969 shares directly, which include 413,312 shares received for no consideration in a pro-rata in-kind distribution from Sera Medicines, LLC.
Climb Bio, Inc. reported a Form 4 showing a grant of stock options tied to 70,284 shares of common stock at an exercise price of $13.36 per share. The options vest in equal monthly installments from June 29, 2026 over three years and expire on June 29, 2036. The options are held by Ms. Celebi for the benefit of several RA Capital funds and an account, and any net cash or stock received upon exercise must be turned over to RA Capital Management, offsetting advisory fees. The reporting persons disclaim beneficial ownership of the option and underlying shares except to the extent of any pecuniary interest.
Climb Bio, Inc. director Breanna Maurine Celebi was granted a stock option covering 70,284 shares of common stock at an exercise price of $13.36 per share. The option vests in equal monthly installments starting on June 29, 2026 and continuing until the third anniversary of that date, contingent on continued service. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising this option must be turned over to RA Capital-managed funds and an account to offset advisory fees, and the reporting person therefore disclaims beneficial ownership of the option and its underlying shares.
Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction. On June 27, 2026, 68,750 RSUs converted into the same number of common shares as part of a four-year vesting grant. On June 29, 2026, Brennan sold 30,902 common shares at a weighted average price of $13.17 per share pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations tied to the RSU vesting. After these transactions, Brennan directly owned 87,731 common shares, including 1,751 acquired through the employee stock purchase plan, and continued to hold RSUs scheduled to vest annually over four years.
Climb Bio, Inc. reported a Form 4 showing a compensation-related stock option grant tied to RA Capital–associated entities. An option over 40,000 shares of Common Stock was awarded with an exercise price of $10.55 per share, expiring on June 4, 2036.
According to the footnotes, the option is held by Dr. Andrew Levin for the benefit of RA Capital Healthcare Fund and related Nexus funds and an account, and any net cash or stock from exercise will offset advisory fees owed to RA Capital Management, L.P. The reporting persons, including RA Capital entities and Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of any pecuniary interest. The option vests on the earlier of June 5, 2027 or the day immediately prior to the next annual stockholder meeting, subject to Dr. Levin’s continuous service.
Climb Bio, Inc. director Andrew David Levin was granted a stock option covering 40,000 shares of common stock at an exercise price of $10.55 per share. The option vests on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, contingent on continued service.
According to the disclosure, Levin holds this option for the benefit of RA Capital Healthcare Fund, related Nexus funds, and a separately managed account under an arrangement with RA Capital Management. Any net cash or stock from exercise must be turned over to the adviser to offset advisory fees, and Levin disclaims beneficial ownership of the option and underlying shares.
Climb Bio, Inc. director Kimberlee C. Drapkin received a grant of stock options covering 40,000 shares of Common Stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. Following this grant, she holds options on 40,000 shares directly. The options will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, subject to her continued service through that date.
Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. These options vest on the earlier of June 5, 2027 or immediately before the next annual meeting of stockholders, subject to his continued service. Following this grant, Williams holds 40,000 options directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Climb Bio, Inc. director Alexander Cumbo reported a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $10.55 per share, expire on June 4, 2036, and vest on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.
Climb Bio director Thomas Stephen Basil received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036.
The options will vest on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, as long as he continues to serve through that date.
Climb Bio, Inc. director Judith Dunn received a grant of stock options representing the right to buy 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. The 40,000 underlying shares will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, as long as she continues to serve through that date. Following this grant, she holds stock options for 40,000 shares directly.
Climb Bio, Inc. reported that investment entities affiliated with RA Capital acquired pre-funded warrants linked to its common stock. The filing shows an indirect grant of 2,106,000 Pre-Funded Warrants, each exercisable for one share of common stock.
The warrants were acquired at $9.4999 per warrant and have a nominal exercise price of $0.0001 per share. They are exercisable immediately and have no expiration date, but their exercise is limited so that RA Capital–affiliated holders and related groups cannot beneficially own more than 33.0% of Climb Bio’s outstanding common stock after exercise. Following this grant, the reporting RA Capital entities show 22,546,000 pre-funded warrants beneficially owned, subject to footnoted pecuniary-interest and beneficial-ownership disclaimers.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 50,000 shares of Common Stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On February 25, 2026, he sold 33,687 shares at a weighted average price of $7.0046 per share, followed by 16,313 shares on February 26, 2026 at a weighted average price of $7.0060 per share. The filing notes that each day’s sales occurred in multiple trades within price ranges from $7.0000 to $7.0600 and from $7.0000 to $7.0400, respectively. After these transactions, Basil directly owned 154,657 shares.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 100,000 shares of common stock in open-market transactions on February 12 and 13, 2026. He sold 90,000 shares at a weighted average price of $5.2332 on February 12 and 10,000 shares at a weighted average price of $5.8141 on February 13.
After these sales, Basil directly beneficially owns 204,657 shares of Climb Bio common stock. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on October 14, 2025, and notes that each reported price reflects a weighted average of multiple individual trades within the disclosed price ranges.
Climb Bio, Inc. reported an equity award to its President and CEO, Brennan Aoife, who also serves as a director. On January 6, 2026, Aoife received a stock option to buy 700,000 shares of Climb Bio common stock at an exercise price of $3.81 per share. The filing shows this option is held directly and represents 700,000 derivative securities beneficially owned after the grant.
The option was granted as a long-term incentive. According to the vesting terms, 25% of the underlying shares vest on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as Aoife continues to serve the company. The option has an expiration date of January 5, 2036, giving a long window in which it can be exercised if vested.
Climb Bio, Inc. (CLYM) reported a stock option grant to Chief Business Officer Megan Wilson Perrin on a Form 4. On January 6, 2026, she received a stock option to buy 300,000 shares of common stock at an exercise price of $3.81 per share, expiring on January 5, 2036.
According to the vesting terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments through January 6, 2030, conditioned on her continued service with the company.
Climb Bio, Inc. reported that its Chief Financial Officer, Susan Altschuller, received a new stock option grant. On January 6, 2026, she was awarded a stock option to buy 142,500 shares of Climb Bio common stock at an exercise price of $3.81 per share. Following this grant, she beneficially owned 142,500 derivative securities in the form of this option, held directly.
The option vests over time. According to the disclosure, 25% of the shares vest on the first anniversary of the January 6, 2026 grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as she continues in service. The option expires on January 5, 2036.
Climb Bio, Inc. reported that Senior Vice President, Finance Cindy Driscoll received a grant of stock options. On January 6, 2026, she was awarded a stock option to buy 100,000 shares of common stock at an exercise price of $3.81 per share.
According to the grant terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments through January 6, 2030, as long as she continues in service. Following this grant, she beneficially owns 100,000 stock options directly.
Climb Bio, Inc. (CLYM) reported an insider purchase by investment funds managed by RA Capital. On January 5, 2026, RA Capital Healthcare Fund, L.P. bought 7,111 shares of Climb Bio common stock at a weighted average price of about $3.50 per share. After this transaction, entities advised by RA Capital collectively reported 3,403,429 shares held indirectly through RA Capital Healthcare Fund, L.P., along with additional indirect holdings through Sera Medicines, LLC, RA Capital Nexus Fund, L.P., RA Capital Nexus II Fund, L.P., RA Capital Nexus III Fund, L.P., and a separately managed account. RA Capital Management, L.P., its affiliated entities, and individuals Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their roles but disclaim beneficial ownership except to the extent of their pecuniary interest.
Climb Bio director and 10% owner entities affiliated with RA Capital reported a major restructuring of their holdings and additional open-market share purchases. On December 11, 2025, RA Capital Healthcare Fund, L.P. exchanged 20,440,000 shares of Climb Bio common stock for a pre-funded warrant exercisable for up to 20,440,000 shares at an exercise price of $0.0001 per share, for no additional consideration.
The filing also reports open-market purchases of Climb Bio common stock: 213,099 shares on December 11, 2025 at a weighted average price of $2.18 per share and 101,462 shares on December 12, 2025 at a weighted average price of $2.86. The warrant has no expiration date, is exercisable immediately, and includes a 33.0% beneficial ownership cap, limiting how many shares can be exercised based on total outstanding stock. Climb Bio shares are held across multiple RA Capital funds and a separately managed account, with beneficial ownership relationships detailed among the affiliated entities.
Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.